Covex S.A. creates 2000 jobs with the onset of a new agroindustrial project in Latin America

Covex S.A.Covex S.A., leader in the manufacture of products aimed at improving cerebral functions, successfully reaches the first stage of its introduction in Latin America, as it begins to harvest medicinal plants on an industrial scale, for the onset of its new agroindustrial expansion.

At the same time, Covex will transfer its patented technologies for the obtention of the pharmaceutical active ingredients. Dr. Fernando Calvo, President of Covex S.A., states: "This project will reap benefits, not only in terms of greater manufacturing competitiveness, but also in the form of social consequences in those countries where it is to be introduced."

Maria Eugenia Lima, President of Fundación Mujer y Familia Andina, Ecuadorian Farm workers Cooperative Organization associated with Covex, declares that the agricultural development reached has been a success, with highly satisfactory yields, thanks to the highly capable farm workers in Ecuador, alleviating the damaged profitability of the Ecuadorian coffee growers.

On his part, Fernando Posada, President of Extracciones Naturales S.A. de C.V. Mexico, another industrial partner of Covex, comments: "We are very satisfied about playing an integral part in this project, as our vast experience and the excellent quality of our facilities makes our company ideal for successfully receiving and introducing this technological transfer from Spain."

About Covex S.A.
Since 1977 Covex has specialized in R+D+i, production, and commercialization of nutraceutical and pharmaceutical products aimed at improving brain functions, (memory, attention, etc.). These include the drug Vinpocetine Covex 5mg, and the nutraceuticals: Intelectol® or its award winning "Memory drinks" such as Memocafe® or Memotea®, Memocola®, etc.

After a quarter of a century of R+D+i, leading the way in the production of goods derived from the Vinca family in the world, Covex has been exporting since 1980, more than 95% of its production to 60 countries, and currently has subsidiaries abroad.

The business activity is based on price competitiveness and high quality, and on the immediate delivery of its products around the globe. The company presently possesses over 200 patents and trademarks in more than 100 countries.

For more information, visit www.covex.com.

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 2...